Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type a: Results from the botulinum toxin for the upper limb after stroke (BoTULS) trial

Toxins

Volumn 4, Issue 12, 2012, Pages 1415-1426

  Shackley, Phil ^a   Shaw, Lisa ^b   Price, Christopher ^b   van Wijck, Frederike ^c   Barnes, Michael ^d   Graham, Laura ^d   Ford, Gary A ^b   Steen, Nick ^b   Rodgers, Helen ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^d TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Botulinum toxin type A; Cost effectiveness; Stroke; Upper limb spasticity

Indexed keywords

BOTULINUM TOXIN A; SPASMOLYTIC AGENT;

ADULT; ARM DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PROBABILITY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SOCIAL WORK; SPASTICITY; TREATMENT DURATION; UNITED STATES; UPPER LIMB SPASTICITY;

BOTULINUM TOXINS, TYPE A; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HUMANS; MUSCLE SPASTICITY; PHYSICAL THERAPY MODALITIES; QUALITY-ADJUSTED LIFE YEARS; STROKE; UPPER EXTREMITY;

EID: 84870751365     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4121415     Document Type: Article

References (22)

1. Youman, P.; Wilson, K.; Harraf, F.; Kalra, L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003, 21, 43-50.
2. Evers, S.M.A.A.; Struijs, J.N.; Ament, A.J.H.A.; van Genugten, M.L.L.; Jager, J.H.C.; van den Bos, G.A.M. International comparison of stroke cost studies. Stroke 2004, 35, 1209-1215.
3. Saka, O.; McGuire, A.; Wolfe, C. Cost of stroke in the United Kingdom. Age Ageing 2009, 38, 27-32.
4. Reducing Brain Damage: Faster Access to Better Stroke Care; National Audit Office: London, UK, 2005.
5. Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke, 3rd ed.; Royal College of Physicians: London, UK, 2008.
6. Spasticity in Adults: Management Using Botulinum Toxin: National Guidelines; Royal College of Physicians: London, UK, 2009.
7. Dolly, J.O.; Aoki, K.R. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 2006, 13, 1-9.
8. Garces, K.; McCormick, A.; McGahan, L.; Skidmore, B. Botulinum Toxin A for Upper and Lower Limb Spasticity: A Systematic Review; (Technology report no 51) Canadian Coordinating Office for Health Technology Assessment: Ottawa, Canada, 2005.
9. Hesse, S.; Reiter, F.; Konrad, M.; Jahnke, M.T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: A randomized, double-blind, placebo-controlled trial. Clin. Rehabil. 1998, 12, 381-388.
10. Bhakta, B.B.; Cozens, J.A.; Chamberlain, M.A.; Bamford, J.M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J. Neurol. Neurosurg. Psychiatry 2000, 69, 217-221.
11. Brashear, A.; Gordon, M.F.; Elovic, E.; Kassicieh, V.D.; Marciniak, C.;Do, M.; Lee, C.H.; Jenkins, S.; Turkel, C. Botox post-stroke spasticity study group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N. Engl. J. Med. 2002, 347, 395-400.
12. Shaw, L.; Price, C.; van Wijck, F.; Shackley, P.; Steen, N.; Barnes, M.; Ford, G.; Graham, L.; Rodgers, H. Botulinum toxin for the upper limb after stroke (BoTULS) trial: Effect upon impairment, activity limitation and pain. Stroke 2011, 42, 1371-1379.
13. Guide to the Methods of Technology Appraisal; National Institute for Clinical Excellence: London, UK, 2004.
14. Curtis, L. Unit Costs of Health and Social Care; PSSRU, University of Kent: Canterbury, UK, 2007.
15. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 53; BMJ Publishing Group Ltd and RPS Publishing: London, UK, 2007.
16. Brooks, R. EuroQol: The current state of play. Health Policy 1996, 37, 53-72.
17. Dolan, P. Modeling valuations for EuroQol health states. Med. Care 1997, 35, 1095-108.
18. Richardson, G.; Manca, A. Calculation of quality adjusted life years in the published literature: A review of methodology and transparency. Health Econ. 2004, 13, 1203-1210.
19. O'Brien, B.; Briggs, A.H. Analysis of uncertainty in health care cost-effectiveness studies: An introduction to statistical issues and methods. Stat. Methods Med. Res. 2002, 11, 455-468.
20. Schafer, J.L. Analysis of Incomplete Multivariate Data; Chapman and Hall: London, UK, 1997.
21. Rawlins, M.D.; Culyer, A.J. National institute for clinical excellence and its value judgments. BMJ 2004, 329, 224-227.
22. Ward, A.; Roberts, G.; Warner, J.; Gillard, S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J. Rehabil. Med. 2005, 37, 252-257.